On June 10, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, reported it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating that Pressure-Enabled Drug Delivery (PEDD) delivered a 48% improvement in drug delivery to target tumors while reducing complications associated with off-target administration when compared with conventional embolization approaches — results with meaningful implications for the estimated 900,000 patients diagnosed annually worldwide with primary liver tumors or liver metastases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alexander S. Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital (Newport Beach, CA), will join TriSalus management to discuss the current treatment landscape for hepatocellular carcinoma (HCC) and liver metastases, how the new real-world evidence shapes patient selection and treatment strategy, and share clinical experience and case examples using the TriNav Infusion System. A live Q&A session will follow the formal presentations, providing direct engagement with management and Dr. Misono.

Event: Virtual KOL Webinar

Date: Wednesday, June 24, 2026

Time: 8:00 AM ET

Speaker: Alexander S. Misono, MD, MBA, RPVI — Chief of Interventional Radiology, Hoag Hospital

Register: View Source

"The publication of this real-world evidence marks an important milestone in demonstrating the clinical and economic value of PEDD technology for patients undergoing liver embolization. We look forward to a rich discussion with Dr. Misono on how these findings can help interventional oncologists optimize treatment decisions and improve outcomes for their patients."

— Mary Szela, President & CEO, TriSalus Life Sciences

The TriNav Infusion System is one of three FDA-cleared devices in the TriSalus platform that utilize the PEDD approach to deliver therapeutics directly to liver and pancreatic tumors. The technology is designed to modulate pressure and flow to maximize drug delivery to the tumor while reducing undesired delivery to healthy tissue.

(Press release, TriSalus Life Sciences, JUN 10, 2026, View Source [SID1234666548])

On June 10, 2026 Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, reported a multi-year collaboration with Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collaboration expands the existing relationship between the companies and reflects a shared commitment to unlock the full value of induced proximity approaches in drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Novartis and Orionis will use Orionis’s Allo-Glue platform, together with its AI-driven discovery engine, to accelerate target and ligase profiling and molecular glue optimization. These integrated capabilities enable the systematic discovery of small molecule glues that modulate therapeutic targets through induced proximity mechanisms. Orionis will receive an upfront payment of USD 40 million and is eligible to receive research, development, and commercial milestone payments of up to USD 1.4 billion, in addition to tiered royalties on net sales of collaboration products.

"We are proud to renew and expand our collaboration with Novartis," said Niko Kley, Chief Executive Officer of Orionis Biosciences. "Having such a partner continue to engage deeply with us is a strong validation of the value of our molecular glue platform and the progress we have achieved toward rational and scalable discovery of this emerging drug class."

"Our recent advances in AI and robotic automation have accelerated all aspects of molecular glue discovery, from systematic prioritization of productive target–ligase pairs to glue candidate discovery and optimization," said Riccardo Sabatini, Chief Data Scientist at Orionis Biosciences. "This is exactly the kind of platform maturity that makes collaborations like this possible."

"We are excited to deepen our collaboration with Orionis and to explore the full potential of molecular glue modalities across multiple therapeutic areas," said John Tallarico, Head of Discovery Sciences at Novartis. "The Orionis platform offers an opportunity to rapidly uncover and design molecular glue mechanisms, enabling us to expand the horizon of targetable biology for future therapies."

(Press release, Orionis Biosciences, JUN 10, 2026, View Source [SID1234666549])

On June 10, 2026 PhoreMost Limited ("PhoreMost"), a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, reported its lead programme, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. The milestone marks the Company’s progress towards first-in-human clinical trials, with a pipeline of differentiated and first-in-class assets in oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PMC-001 is a highly differentiated, orally bioavailable MTA, positioned to treat primary brain cancers, including glioblastoma, and secondary brain cancers frequently metastasising from advanced lung, breast and other tumour types, with strong potential for further indication expansion. While existing MTAs, such as taxanes, are broadly effective against multiple cancer types, they exhibit a lack of oral bioavailability and blood-brain barrier penetration. Primary and secondary brain cancers represent areas of significant unmet clinical need and high prevalence, creating a multibillion-dollar market opportunity.

PMC-001 is a small molecule with favourable drug-like properties possessing oral activity, CNS-penetration and ease of scaling. Preclinical safety and toxicology studies have demonstrated strong anti-tumour efficacy with excellent tolerability across diverse oncology-focussed models with an attractive dosing regimen. CMC has now been completed and PhoreMost is preparing imminent regulatory filings for trial initiation. The programme originates from the Company’s longstanding collaboration with Sentinel Oncology, with PhoreMost now taking the candidate forward.

Gabriel Fox, MB BChir, joins PhoreMost as Consulting Chief Medical Officer to lead the clinical development of PMC-001. Dr Fox completed his medical training at the University of Cambridge and brings 30 years of industry experience from global pharmaceutical companies such as Roche and Gilead Sciences, spanning the entire drug development process.

Dr Neil Torbett, CEO of PhoreMost, said: "PMC-001 shows striking tumour growth inhibition and holds great promise in delivering clinical benefit to patient groups that represent the highest areas of unmet need – announcing the programme is a fantastic milestone. With Gabriel’s extensive experience, we are excited to build on the impressive preclinical proof points and progress towards first-in-human trials, to deliver on our promise of unlocking the next generation of medicines."

Dr Gabriel Fox, Consulting CMO of PhoreMost, added: "I am thrilled to be joining PhoreMost as it reaches this significant milestone and approaches clinical stage. PMC-001 has performed exceptionally well in preclinical studies, the nature of the asset and mechanism of action is particularly impressive and will deliver clinical efficacy inflections rapidly. PMC-001 is well positioned to make a real difference. Having seen first-hand the patient need for new treatment options for both primary brain cancers and cancers with brain metastases, I am excited to be a part of the team moving it into the clinic."

(Press release, PhoreMost, JUN 10, 2026, View Source [SID1234666550])

On June 10, 2026 Abeona therapeutics presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Abeona Therapeutics, JUN 10, 2026, View Source [SID1234666536])

On June 10, 2026 Cosylab and Heron Neutron Medical Corp. reported the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT’s international market access and business development. By combining Cosylab’s proven expertise in mission-critical software and complex system integration with Heron’s end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality.

"AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologies and expanding our reach in the Asia-Pacific region and beyond. We are committed to delivering impactful joint projects with Heron that accelerate market readiness and clinical adoption."

"This agreement represents a key step in Heron’s international growth strategy," underlined Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp. "Working with Cosylab will strengthen our cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in markets worldwide."

(Press release, Heron Neutron Medical, JUN 10, 2026, View Source [SID1234666551])